

ForPatients

by Roche

Colorectal Cancer (CRC)

A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02673710 ML29985

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to explore the relationship between sarcopenia, as defined by computed tomography, treatment related outcomes and other body composition related parameters in a patient population receiving bevacizumab beyond progression.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02673710 ML29985
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
